CHARACTERIZING THE MECHANISM OF ACTION (MOA) OF INVESTIGATIONAL/APPROVED CANCER AGENTS

$56.59M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Leidos Biomedical Research, Inc.
Country	United States
Start Date	Sep 22, 2023
End Date	Sep 21, 2028
Duration	1,826 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	NIH (US)
Grant ID	`10941126`

Grant Description

The Division of Cancer Treatment and Diagnosis (DCTD), NCI, is requesting support to develop capability for performing molecular mechanistic studies of approved and investigational agents in various biochemical, cellular and in vivo systems.

This molecular pharmacology capability will enable NCI to elucidate drug mechanisms of action (MOA) in the context of cellular pathways, tumor heterogeneity, emergence of drug resistance, and immunological response.

This project focuses on dissecting molecular pathways in response to drug treatment to elucidate an MOA to advance pre-clinical therapeutic investigations by the NCI.